Non-invasive Glioma Characterization Through Molecular Imaging

Last updated: January 24, 2025
Sponsor: University of Miami
Overall Status: Active - Recruiting

Phase

N/A

Condition

Brain Tumor

Memory Loss

Brain Cancer

Treatment

3T MRI Scanner

Clinical Study ID

NCT03684109
20180606
  • Ages > 18
  • All Genders

Study Summary

MRI-based sequences can provide non-invasive quantification of intratumoral 2-hydroxyglutarate (2HG) distribution and tumor cellularity in human gliomas and help guide the development of novel glioma therapies.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Adults (≥18 year old)

  • Subjects with suspected or confirmed gliomas and who will have a medically indicatedbiopsy or resection of his/her brain lesion.

Exclusion

Exclusion Criteria:

  • Adults unable to consent

  • Individuals who are not yet adults (infants, children, teenagers)

  • Pregnant women

  • Patients unable to have MRI done

Study Design

Total Participants: 30
Treatment Group(s): 1
Primary Treatment: 3T MRI Scanner
Phase:
Study Start date:
January 25, 2019
Estimated Completion Date:
January 31, 2026

Study Description

This is a pilot study aiming at developing and optimizing MRI-based sequences to provide non-invasive quantification of intratumoral 2-hydroxyglutarate (2HG) distribution and tumor cellularity in human gliomas and help guide the development of novel glioma therapies.

Connect with a study center

  • University of Miami

    Miami, Florida 33136
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.